Atlas.
Sign inStart free trial
IMCRNASDAQ · US

Immunocore Holdings plc

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Bahija Jallal
Founded
—
IPO Date
—
HQ
Oxfordshire, United Kingdom
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$31.65 ▼ 6.3%
Last (1 Jul 2026) · $32
Period High · $35.29
Period Low · $0.00
52W: $31.65 – $40.22

Key Metrics

Share Price
$31.65
-0.3% today
Market Cap
$1.6B
P / E
—
EV / Revenue
2.8x
Revenue Growth
+28.9%
year-on-year
Gross Margin
—
Enterprise Value
$1.1B
52W High
$40.22
52W Low
$0.00
Avg Volume
455K
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
3 known institutional holders·$13M total on record·2026-Q1
Price T Rowe Associates Inc
34.7%·$15,794
State Street Corp
16.9%·$8M
BlackRock, Inc.
12.6%·$6M
Free Float
35.8%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Immunocore Holdings plc
OverviewImmunocore Holdings plc share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Immunocore Holdings plc generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsImmunocore Holdings plc's complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityImmunocore Holdings plc executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsImmunocore Holdings plc's annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Immunocore Holdings plc, updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Immunocore Holdings plc aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersImmunocore Holdings plc valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Immunocore Holdings plc with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Immunocore Holdings plc — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial